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Background: Systematic evaluation of psychosocial distress in oncology outpatients is an important issue. We
assessed feasibility and beneﬁt of standardized routine screening using the Distress Thermometer (DT) and Problem
List (PL) in all patients of our community-based hematooncology group practice.
Patients and methods: One thousand four hundred forty-six patients were screened between July 2008 and
September 2008. Five hundred randomly selected patients were sent a feedback form.
Results: The average distress level was 4.7, with 37% indicating a distress level >5. Patients with nonmalignant
diseases (81% autoimmune diseases or hereditary hemochromatosis) showed the highest distress level of 5.2. Most
distressed were patients who just learned about relapse or metastases (6.4), patients receiving best supportive care
(5.4) and patients receiving adjuvant antihormonal therapy (5.4). Ninety-seven percent of patients appreciated to speak
to their doctor about their distress. Fifty-six percent felt better than usual after this consultation.
Conclusion: DT and PL are feasible instruments to measure distress in hematooncology outpatients receiving
routine care. DT and PL are able to improve doctor–patient communication and thus should be implemented in routine
patient care. The study shows that distress is distributed differently between individuals, disease groups and treatment
phases.
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introduction
Apart from the physical impairment, psychosocial distress is a
major burden for around one-third of oncology patients [1–7].
There is also evidence that a high distress level correlates with
a number of negative outcomes like decreased medical
adherence, greater desire for death, increased morbidity and
length of hospital stays [8–14]. However, the consequences for
routine care especially within outpatient settings so far have
been little. According to experts, the transfer of psycho-
oncological ﬁndings into daily practice has been highly
insufﬁcient. Most oncologists rely only on their own estimation
when assessing their patients’ distress level. This results in
a great number of misjudgments [3–15]. One important aim of
current research is to systematically and effectively identify
patients who are suffering from high emotional distress as
a precondition to ﬁnd appropriate measures to improve their
situation. Resident oncologists accompany their patients very
closely and sometimes over a long time within these painful
phases of their lives. On this account, it is the oncologist’s
duty not only to look after the patients’ physical condition but
also to care about their psychological well-being. Although
studies have shown that physicians tend to strongly underrate
their patients’ psychosocial distress when relying on their
personal appraisal [16–18], only between 10% and 14% of
cancer specialists are using standardized screening
instruments [19, 20]. Since furthermore both subjective
perception of distress and the way patients talk about these
issues vary to a great extent, transsectoral standards have to be
established and implemented to reliably identify patients
requiring speciﬁc intervention due to their high level of
distress.
The National Comprehensive Cancer Network’s Distress
Thermometer (DT) and Problem List (PL) are brief
instruments to evaluate patients’ extent and sources of distress
[21]. The DT has been validated within various international
studies [22–27] and seems to be a reasonable instrument to
overview the patients’ level of distress. Across the different
indications and cultural backgrounds, these studies reported
cutoff scores between >3 and >6. Based on the German
adaptation by Mehnert et al. [28], the Research Group for
Psycho-Oncology of the German Association for Hematology
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recommends the routine use of the DT and PL in German
oncology patients with a cutoff score >5 as an indicator to refer
the patient to psychosocial service [29]. We decided to use this
ultrashort screening method although accuracy has been
proven to be rather moderate [30]. But at the same time we
expected the patients’ acceptance to participate to be high since
it is easy to understand and does not make demands on their
time.
With this study, we wanted to explore the DT’s and PL’s
feasibility in routine care of a community-based
hematooncology group practice in Germany. During the last
20 years, >300 community-based hematooncology group
practices have been established in Germany caring for >500 000
patients per year. Therefore, having an instrument that could
easily be implemented in daily practice for the assessment of
psychosocial distress and that would be able to improve
doctor–patient communication would be of great practical
relevance. Furthermore, we expected the instrument to provide
sufﬁcient information to talk more effectively about
psychosocial matters.
Therefore, it was our intention to test the instrument’s
practicability as a ﬁrst-stage screen in daily practice and
in which way it contributes to an improvement of the
subsequent doctor–patient communication on
psychosocial issues. Moreover, we wanted to explore the
subjectively perceived level of distress in patients with
different diseases undergoing different treatment forms and
phases.
Since DT and PL never have been evaluated in routine care
outside academic institutions, the aim of the study was to
answer three main questions concerning routine patient care in
a community-based hematooncology group practice in
Germany:
1 Is it feasible to use the DT and PL in routine care?
2 Does the use of DT and PL improve patient–doctor
communication?
3 How is distress distributed between outpatients suffering
from different diseases and patients within different
treatment phases?
patients and methods
All 1446 patients visiting our oncology group practice between July 2008
and September 2008 were asked to complete the DT and PL, a single-item
rapid screening tool for distress. On this visual analog scale, patients
range their level of distress between ‘0’ (none) and ‘10’ (extreme). On the
36-item PL, the patients indicated speciﬁc problems as their individual
sources of distress. The list consists of speciﬁc aspects from the areas of
practical problems, family-related problems, emotional problems, spiritual/
religious problems and physical problems. The distress score is being
deduced from the information on the DT. The PL provides further
information on the nature of the individual patient’s distress. DT and PL
are depicted in detail in Figure 1.
As a cutoff level to consider a patient as highly distressed, we chose
a score >5 as it was constituted by the AK Psycho-Onkologie der DGHO.
The questionnaire was ﬁlled in while the patients were waiting for the
appointment with their doctor. Patients were instructed how to use the tool
by staff from the reception desk who also handed the form over to the
patient. Most patients answered the questions independently or with the
help of their accompanying person. In case patients needed actually further
assistance, they received help from their oncologist at the beginning of their
consultation visit. The contents then were immediately discussed between
doctor and patient. Using another questionnaire, the doctor classiﬁed the
patient regarding his or her disease, the current form and phase of
treatment as well as the recommended or conducted measures of
intervention. Possible measures of intervention by the oncologist were as
follows:
Figure 1. Distress thermometer (DT) and problem list (PL).
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2 Referral to psychotherapy
3 Referral to the local cancer society counseling team
4 Psychopharmacotherapy
5 Handing out information material
6 Recommendation for rehabilitation
At the same time, a group of 474 women participating in a mammography
screening program (MSP) was asked also to complete the DT and PL as
a reference group for our breast cancer patients (BCPs).
In order to assess the patients’ judgment of the DT’s inﬂuence on the
conversation with their doctor, a random sample of 500 study participants
was sent a self-constructed ﬁve-item feedback form (see Figure 2).
Accompanying an explanatory letter, the questions and predetermined
response options were the following:
1.) What do you think in general about talking to your oncologist about
emotional distress?
a. I appreciate that
b. I do not appreciate that
2.) How did you perceive the previously held conversation with your
oncologist, when you talked about the results of the questionnaire?
a. I think it was good
b. I don’t think my problems were addressed appropriately
c. I did not report any problems on the questionnaire
d. I don’t remember us talking about my psychosocial distress
3.) Would you proactively speak to your oncologist about your
psychosocial distress?
a. Yes, in this respect my oncologist is a very important contact person for
me
b. I wouldn’t bring it up proactively, but in general I would like to talk to
my oncologist about these issues
c. No, I don’t want to talk to my oncologist about emotional problems
4.) Do you think the questionnaire contributed to a more targeted
conversation about your problems?
a. Yes it helped a lot
b. I don’t need help to put my problems into words
c. No, this was still difﬁcult for me
5.) How did you feel after this conversation?
a. Better than usual
b. Worse than usual
c. As always
statistics
Descriptive analysis was carried out for patient characteristics and data
from the feedback form. Analysis of variation was carried out to compare
the distress level regarding patient characteristics (disease group, age group,
treatment phase, BCP versus MSP). Using chi-square test for heterogeneity,
we compared the prevalence of problems from the PL for BCP versus MSP.
Pearson’s r was calculated to describe the correlation between age and
distress score and the number of problems (total number, number of
emotional problems and number of physical problems, respectively). All
statistical analyses were carried out using SPSS software (SPSS Inc.,
Chicago, IL).
results
patient characteristics
One thousand four hundred ninety patients were eligible for
this study. Forty-four (3.0%) patients refused to participate or
were unable to answer the questions. A total of 1446
patients were eventually enrolled in the study. The median age
was 66 years. Forty-three percent were male and 57% were
female. The sample comprises 620 (43%) patients with
hematological neoplasms, 598 (41%) patients with solid
tumors, 154 (11%) patients with benign hematological diseases
and 74 (5%) patients with other nonmalignant diseases
(mostly with an autoimmune disease or hemochromatosis).
Regarding treatment phases, most patients were under
observation (19%), receiving palliative i.v. chemotherapy
(16%) or oral chemotherapy only (15%). Full patient
characteristics are depicted in Table 1.
distress scores and problems
One thousand three hundred thirty-four of 1446 patients rated
their distress level on the DT and showed a mean score of 4.7.
Thirty-seven percent rated their distress >5 and therefore
required speciﬁc intervention.
Table 2 shows that younger patients suffer more distress than
older patients. A signiﬁcant negative correlation between age
and distress score was seen (r = 20.122; P < 0.001). However,
distress rises again after the age of 80 years, with females scoring
higher (4.9) on the DT than males with a mean level of 4.5.
Among the patients of our practice, patients with malignant
diseases are not necessarily those to mention the highest levels
of distress. On average, patients with nonmalignant non-
hematologic diseases—this patient population consisted of
patients mostly with autoimmune diseases or
hemochromatosis—showed the highest degree of distress (5.2)
(Table 3). Considering the treatment phases, the highest level of
distress was seen in patients who just learned about their
diagnosis of relapsed or metastatic disease (6.4), who received
best supportive care (5.4) as well as patients undergoing
adjuvant antihormonal treatment (5.4). Figure 2. Feedback questionnaire.
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patients with early-stage chronic lymphocytic leukemia not yet
requiring medical treatment—showed the lowest average
distress level of 4.2.
From the PL, the most prevalent problems were fatigue
(49%), pain (44%), impaired mobility (41%) and sleep
disturbances (41%). A signiﬁcant correlation was seen between
the distress score and the total number of reported problems
from the PL (r = 0.529; P < 0.001). Correlations were also
observed between the distress score and the number of
emotional problems (r = 0.460; P < 0.001) and the number of
physical problems (r = 0.442; P < 0.001), respectively. The
number of physical and emotional problems also correlated
signiﬁcantly (r = 0.434; P < 0.001).
measures of intervention
Concerning the recommended or conducted measures of
intervention, in 70% of all cases, the doctor intervened by
Table 1. Patient characteristics
Patient characteristics n %
Gender
Male 617 43
Female 829 57
Age (years)
<50 246 17
50–59 271 19
60–69 395 27
70–79 395 27
‡80 139 10
Diagnoses
Hematological neoplasms 620 43
Myeloproliferative disease 184 30
Non-Hodgkin’s lymphoma 137 22
Chronic lymphocytic leukemia 106 17
Multiple myeloma 76 12
Myelodysplastic Syndrome 59 10
Hodgkin’s disease 18 3
Hairy cell leukemia 15 2
Acute myeloid leukemia 14 2
Acute lymphocytic leukemia 8 1
Other lymphocytic leukemia 3 0.5
Solid tumors 598 41
Breast 236 39
Digestive organs 103 17
Respiratory and intrathoracic organs 65 11
Male genital organs 64 11
Female genital organs 33 6
Urinary tract 27 5
Skin 17 3
Cancer of unknown primary 13 2
Eye, brain, CNS 11 2
Mesothelialan soft tissue 11 2
Lip, oral cavity and pharynx 8 1
Thyroid and other endocrine glands 6 1
In situ neoplasms 2 0.3
Bone and articular cartilage 2 0.3
Benign hematological diseases 154 11
Anemia 53 34
Purpura and other hemorrhagic
conditions
31 20
Other diseases of blood and blood-
forming organs
30 19
Monoclonal gammopathy 19 12
Common variable immunodeﬁciency
syndrome
14 9
Coagulation defect 6 4
Exclusion of disease 1 1
Other nonmalignant diseases 74 5
Autoimmune disease 47 64
Hemochromatosis 13 18
Infection 6 8
Other nonmalignant diseases 5 7
Benign neoplasms 2 3
Exclusion of disease 1 1
Treatment phases
Observation 270 19
Palliative chemotherapy 225 16
Table 2. Distress scores by age groups
Distress by age group (years) Mean SD P
<50 5.4 2.78 <0.001
50–59 5.2 2.54
60–69 4.6 2.90
70–79 4.2 2.80
‡80 4.5 2.96
SD, standard deviation.
Table 1. (Continued)
Patient characteristics n %
Oral chemotherapy only 217 15
Other therapy (mostly bisphosphonates
or immunosuppressive therapy)
139 10
Follow-up 126 9
Patients within diagnostic workup 122 8
Best supportive care 88 6
Palliative antihormonal therapy 62 4
Adjuvant chemotherapy 60 4
Adjuvant antihormonal therapy 52 4
Advice/second opinion 50 3
First diagnosis 21 1
Diagnosis of relapse/metastases 14 1
CNS, central nervous system.
Table 3. Distress scores by disease groups
Distress by disease group Mean SD P
Other nonmalignant diseases 5.2 2.83 0.033
Solid tumors 4.9 2.86
Benign hematologic diseases 4.7 2.77
Hematologic neoplasms 4.5 2.78
SD, standard deviation.
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Prescription of antipsychotic drugs or referral to
a psychotherapist was effected in 6%, respectively. A small
number of patients were recommended to consult the local
cancer information center (2%), to start certain rehabilitation
measures (2%), or were handed information material (1%),
though in 28% of distressed patients no intervention was
recommended or carried out.
patient feedback
Two hundred thirty-nine of 500 randomly selected patients
returned the feedback form by means of which they were asked
to give their opinion on the usefulness of the DT and PL for the
doctor–patient communication. Ninety-seven percent indicated
that they appreciated talking to their doctor about their
psychosocial situation. However, for 17%, the initiative had to
come from the doctor since they did not consider it appropriate
to bring up these topics. One hundred twenty-seven patients
regarded themselves as distressed and remembered talking with
their doctor about the DT and PL. Fifty percent of these patients
perceived the DT and PL as helpful to talk about their distress
more precisely. Fifty-six percent stated that they felt better than
usual after this consultation. Only one patient felt worse than
usual and the rest of patients felt as always (28%) or did not
answer this question (16%).
subgroup analysis: BCPs versus mammography
screening participants
The subgroup analysis of BCPs with a median age of 62 years
compared with participants of an MSP with a median age of 59
years revealed signiﬁcantly different distress levels of 5.2 for
BCP versus 3.3 for MS (P < 0.001). Forty-two percent of BCP
scored >5 versus 21% of MSP (P < 0.001). In both groups, there
was a signiﬁcant reverse correlation between age and distress
score (MSP: r = 20.158; P = 0.002; BCP: r = 20.161; P = 0.016).
In BCP, distress continues to decline also after the age of 80
years. Table 4 shows the distress scores of BCP by treatment
phase. Again patients who just found out they had cancer (8.8)
and patients receiving best supportive care (7.0) showed the
highest distress. Patients undergoing adjuvant antihormonal
treatment showed higher distress scores (5.7) than patients
under adjuvant chemotherapy (4.3) or palliative therapy
(chemotherapy: 5.2; antihormonal therapy: 4.9). The most
prevalent problems for BCP were fatigue (58%), fears (53%),
sleep disturbances (52%) and pain (50%). The relative risk
compared with MSP was 2.1, 2.5, 1.4 and 1.6, respectively. The
relative risk for sadness, depression, worry and nervousness
was 2.6, 2.1, 1.7 and 1.6, respectively. These differences in risk
were statistically signiﬁcant. Table 5 shows prevalence of all
problems from the PL for BCP and MSP.
discussion
During the last 20 years >300 community-based
hematooncology group practices have been founded in
Germany caring for >500 000 patients per year. An instrument
that could reliably assess psychosocial distress, improves
doctor–patient communication and could easily be
implemented in daily practice, would be highly relevant for
routine care. DT and PL have been studied extensively in
academic institutions. To the best of our knowledge, this is the
ﬁrst study evaluating the DT and PL in routine care of
outpatients treated in a community-based group practice. With
this study we wanted to answer three main questions:
1. Is it feasible to use the DT and PL in routine care?
The answer unequivocally is yes! From 1490 patients, 1446
(97%) could ﬁll out the form. No signiﬁcant additional
workload was created by using the DT and PL in routine
care. As a consequence of the positive results of our study,
we decided to continue using the DT and PL in daily
practice. As from now, every patient in our practice is
asked to complete the DT and PL on a regular basis.
2. Does the use of the DT and the PL improve doctor–patient
communication?
The answer is yes! Ninety-seven percent of the patients
returning the feed back form stated that they appreciate
talking to their doctor about their psychosocial situation.
Fifty-six percent stated that they felt better than usual
after this consultation. Although we did not measure
doctor’s satisfaction systematically, all ﬁve oncologists
had the impression that doctor–patient communication
was improved by the DT and PL and that the instrument
should be part of their future routine patient care. Here,
we have to admit some methodological limitations of our
study. Since we did not provide for a comparison group,
our argument that the modiﬁed doctor–patient dialogue
achieved an improvement on the patients’ distress is
based on our impression as well as on the results from
our feedback study. The feedback though was only given
by nearly half of the patients we had contacted. Under
these circumstances, we cannot eliminate the fact that
these results may be biased.
Table 4. Breast cancer patients: distress by treatment phase
Mean SD P
First diagnosis 8.8 1.50 0.025
Best supportive care 7.0 2.45
Advice/second opinion 6.6 2.97
Diagnosis of relapse/
metastases
6.5 4.43
Adjuvant antihormonal
therapy
5.7 2.86
Observation 5.5 2.33
Palliative chemotherapy 5.2 2.54
Oral chemotherapy only 5.2 2.89
Palliative antihormonal
therapy
4.9 2.50
Adjuvant chemotherapy 4.3 2.40
Follow-up 4.3 2.70
Other therapy (mostly
bisphosphonates or
immunosuppressive
therapy)
3.2 3.35
SD, standard deviation.
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different diseases and patients within different treatment
phases in a community-based group practice?
One important result of this study is that psychosocial distress
does not necessarily depend on malignancy or prognosis
of the patient’s disease. Our patient sample features
subgroups with a comparatively good prognosis that
report the same or even higher distress than patient
subgroups with poorer prognoses. Patients with
nonmalignant diseases show the highest distress scores.
BCPs receiving adjuvant antihormonal treatment are also
scoring unexpectedly high compared with BCPs under
palliative treatment. These subgroups require the
oncologist’s permanent watchfulness concerning their
psychosocial condition.
It is known that BCPs are a highly distressed subgroup within
the population of cancer patients [6] and that younger women
undergoing breast cancer treatment report lower quality of life
than older women [4, 31–33] but undergoing adjuvant
antihormonal treatment seems to be an important aspect that
generates psychosocial distress. This is possibly due to the
strong physical and psychological impairment caused by the
hormonal change that comes along with this kind of therapy of
which the beneﬁt remains often unclear. This underlines the
importance of an extended baseline discussion with the patient
to point out consequences and anticipatory beneﬁt of adjuvant
antihormonal treatment.
Against the expectation that this situation is supposed to be
very stressful for patients, the patient population under
observation—mostly patients with chronic lymphocytic
leukemia—shows a relatively low distress proﬁle. Most of these
patients have visited the practice for many years and the
relationship with their doctor is therefore very close and
trustful. This plays an important role for the maintenance of
their stable psychosocial condition. We have evaluated the
instrument in a heterogeneous patient sample representing the
reality of patient care in a community-based group practice.
Although the DT and PL were originally developed for use in
oncology settings, we think that it is also a useful screening
instrument for patients with other chronic diseases (i.e.
autoimmune diseases).
With a view to the shortcomings of the instrument, we have
already mentioned the moderate accuracy with a high rate of
false positives and false negatives. One study also found that
compared with the scores on the HADS, the DT is more anxiety
related than depression related [24]. Originally, the DT is
meant only to be used as a screening tool to identify patients
who require referral to further psychosocial care. Although
a close collaboration between oncologists and mental health
professionals is most important and desirable, patients
reporting a high distress level are not necessarily referred to
psychosocial service. Patients being explicitly or seemingly
distressed are routinely offered to make use of psychosocial
services. In practice, however, the patient has to accept long
waiting periods for these services, which may not be
appropriate to the acuteness of the patient’s psychological
strain. Apart from that, a signiﬁcant proportion of patients
explicitly do not wish to visit a psychotherapist. Through these
conversations we came to another important conclusion.
Further interrogation of some patients who had reported an
extraordinarily high distress level resulted in the knowledge that
their distress originated from a totally different source than
their disease. In most of these cases, psychosocial referral would
have been inappropriate.
Therefore, we considered it important to ﬁnd out that both
oncologists and patients conﬁrmed that the DT and PL
inﬂuenced the doctor–patient communication in a positive way
since it was a useful instrument to speak about psychosocial
issues more targeted. This helps to shape the restricted time of
consultations more effectively and therefore saves time.
The information from the DT and PL served as indicators for
the doctor to ask the right questions. Correspondingly, the ﬁnal
assessment of the patients’ psychosocial needs was made based
on the information from the DT and PL as well as the
information obtained in the following doctor–patient dialogue
and the patient’s wish. A very helpful recommendation for the
Table 5. Problems from the PL
BCP (%) MSP (%) P
Fatigue 58 27 0.000
Fears 53 21 0.000
Sleep 52 37 0.000
Pain 50 31 0.000
Nervousness 47 29 0.000
Getting around 45 23 0.000
Worry 44 26 0.000
Sadness 41 16 0.000
Tingling in hands/feet 38 21 0.000
Skin dry/itchy 30 16 0.000
Eating 24 5 0.000
Nose dry/congested 24 8 0.000
Indigestion 23 14 0.003
Nausea 23 5 0.000
Breathing 23 12 0.001
Feeling swollen 22 12 0.000
Depression 21 10 0.001
Mouth sores 19 7 0.000
Constipation 18 7 0.000
Dealing with partner 16 10 0.038
Changes in urination 15 4 0.000
Sexual problems 14 5 0.000
Appearance 14 5 0.000
Diarrhea 14 7 0.004
Dealing with children 12 7 0.025
Bathing/dressing 11 2 0.000
Work/school 9 12 0.115
Housing 8 4 0.052
Transportation 5 2 0.035
Child care 4 2 0.113
Concerning god 3 2 0.190
Fevers 3 1 0.053
Insurance/ﬁnancial 3 1 0.160
Loss of faith 1 1 0.526
PL, Problem List; BCP, breast cancer patient; MSP, mammography
screening program.
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who suggest a ‘trafﬁc light system’ with a green light for
patients scoring low (0–4) and therefore being treated as usual,
a yellow light for patients scoring 5–6, which requires further
examination, and a red light for patients scoring ‡7 indicating
an excessively increased level of distress. In case of a yellow or
red light, the authors recommend close monitoring, the
discussion of the matter of distress and referral for specialist
intervention if appropriate. In most of the cases, the DT- and
PL-induced conversation on psychosocial problems obviously
had a relieving effect. This impression was conﬁrmed by the
results of our feedback study with more than half of the
patients indicating that they felt better after this conversation
than usual. This clariﬁes again the oncologist’s important role
for comprehensive cancer care. Since health care systems
possess limited resources for psychosocial care, the doctor–
patient conversation on psychosocial distress also seems to be
an economically reasonable ﬁrst measure and helps to better
identify patients who would actually proﬁt from further
psychosocial intervention. A well-functioning doctor–patient
communication correlates with numerous aspects such as
enhanced quality of life, medical adherence and patient
satisfaction, whereas malfunctioning communication is
associated with increased levels of anxiety, depression, anger
and confusion [11, 35–37].
In summary, the DT and PL are very useful screening
instruments for psychosocial distress in cancer patients. Our
impression is that they improved patient–doctor
communication and that they could be easily incorporated into
the daily routine of our community outpatient practice. It was
well received by patients, doctors and medical staff.
Future research should incorporate the aspect if and in which
way an improved doctor–patient communication, which
focuses more on the patient’s psychosocial problems, can
actually reduce the patients’ distress persistently.
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